Date

Sep 10 2020
Expired!

Time

8:30 am - 10:00 am

September 2020 BioBreakfast

Hear from Governor Carney and Delaware Bio Members on Delaware Innovation Combating Covid-19

Although live events aren’t possible right now, our connectivity and collaboration go on! Delaware Bio’s BioBreakfast will be virtual in September 2020! Join us to experience the same great BioBreakfast event in a virtual setting.

Join us virtually on Thursday, September 10th from 8:30 – 10:00 am as we highlight the important work Delaware companies and researchers are doing to address the COVID-19 pandemic, ranging from vaccines to therapeutics to diagnostics and testing to protective gear.

We will be joined by our special guest Governor John Carney who will provide an update on the state’s response to the pandemic and answer your questions.

Attendees will also hear from Steven J. Stanhope, Ph.D., Associate Vice President for Research and Principal Investigator at Delaware INBRE as he provides an overview of the Delaware Journal of Public Health’s latest issues dedicated to the important, collaborative Covid-19 research underway across the state. 

CLICK HERE to learn more

Dr. Jennifer Cheek and Megan Carpenter will join us to provide an overview of Siemens Healthineers FDA Emergency Use Authorization for its laboratory-based total antibody test to detect the presence of coronavirus antibodies. Doug Durney will share an inside look at the launch of ILC Dover’s new healthcare respirator in response to the rising demand for PPE during the COVID-19 crisis. Vance Kershner, President and CEO of Labware will join the conversation to discuss the rollout of their Portable Disease Surveillance Kit.

WHAT IS BIOBREAKFAST

BioBreakfast is Delaware Bio’s signature bi-monthly morning opportunity to connect with the bioscience and life science industry to learn about the industry’s hot topics. This event provides great forums to network with more than 100 professionals from the region over breakfast and coffee and learn about ground-breaking research and news from key members of the life sciences community.

WHY YOU SHOULD ATTEND

  • Hear from and meet with executives at the top life science companies making a difference here in Delaware
  • Connect with new business opportunities
  • Get the pulse on the latest life sciences trends
  • Network with peers and potential partners

EVENT PRICING

Member | FREE

Non-Member | $50

In-Transition | $25

EVENT SPONSORS

                   

DELAWARE BIO EVENT POLICIES

Registration Policy

The “In Transition” rate is available for first-time attendees seeking employment. If you are still searching for employment after the first BioBreakfast and wish to continue attending, we offer you a discounted rate of $25 to attend. The “Non-Member” rate is for those who very occasionally attend our events (no more than two events) or for those who are evaluating whether they wish to join Delaware Bio. This is not intended for individuals who attend every event in a series. If you fall into this category, we ask that you join the organization. Information about membership can be found by contacting us at [email protected].

Please note that Delaware Bio is a member-supported organization, preference is given to our members.  If an event becomes sold out and you are registered as a non-member, we reserve the right to cancel your registration and refund your payment. If you are retired and wish to attend BioBreakfast, we ask that you join the organization as a member, at our new, discounted retired membership level.

When registering please use your company email address, so we can verify membership (if applicable). Registration for our virtual events will end 24-hours before the event is set to begin to ensure you receive the proper communication to join the event. Please register in advance, as it may fill up quickly. Thank you!

Refund Policy

Cancellations must be made in writing, via email to Yvette Murray more than one (1) week prior to the event to receive a refund minus 25% for registration/administrative costs. If the cancellation is made within one week of the event or the attendee is a no-show, Delaware Bio will not issue a refund. If you have any questions or concerns, please contact Yvette Murray.

Hourly Schedule

Event Agenda

8:30 - 8:32
Opening Remarks
Speakers:
Michael Fleming
8:32 - 9:00
Delaware Innovation Combating Covid-19
Speakers:
Governor John Carney
9:00 - 9:20
Delaware INBRE
Speakers:
Steven J. Stanhope Ph.D.
9:20 - 9:32
Siemens Healthineers
Speakers:
Dr. Jennifer Cheek, Megan Carpenter
9:32 - 9:44
ILC Dover
Speakers:
Doug Durney
9:44 - 9:56
LabWare
Speakers:
Vance Kershner
9:56 - 10:00
Closing Remarks
Speakers:
Michael Fleming
Michael Fleming
Michael Fleming
President
Delaware BioScience Association
Governor John Carney
Governor John Carney
Governor of Delaware
Born in Wilmington and raised in Claymont, Governor John Carney has been working for the Delaware people for more than 30 years. John took office as Delaware’s 74th Governor in January 2017, focused on making Delaware’s economy more competitive, preparing Delaware’s children to succeed, and building a long-term sustainable financial plan for the State of Delaware. Working with Delawareans across the state, and with members of the General Assembly, he has made progress on each of those priorities. John has directed new resources to high-needs schools, partnered with the private sector to drive new job creation, and taken steps to lower healthcare costs for Delaware families, businesses, and taxpayers. From 2011 to 2017, John served as Delaware’s lone member of the U.S. House of Representatives. During his three terms in Congress, John worked with members of both parties to find solutions to the most important challenges facing the nation. He supported the revitalization of American manufacturing through the “Make It In America” agenda. He was a lead sponsor of the centerpiece of the Jumpstart our Businesses (JOBS) Act that made it easier for small- and medium-sized businesses to grow and create jobs. John also introduced legislation that was signed into law to prevent critical prescription drug shortages, and he was the lead sponsor on a successful bill to help veterans more easily enter the job market. Prior to his time in Congress, John served two terms as Delaware’s Lieutenant Governor. Between 2001 and 2009, John developed the Lt. Governor’s Challenge to encourage Delawareans to live active, healthier lifestyles. He also created and implemented the Models of Excellence in Education program that allowed schools throughout the state to share best practices. In addition, John was a strong supporter of the Delaware smoking ban and he led the fight for a Cancer Right to Know law, ultimately passed in 2008. John also served as Chairman of the Delaware Healthcare Commission, the Criminal Justice Council, and the Delaware Science & Technology Council. Under then-Governor Tom Carper, John served as Delaware’s Secretary of Finance and Deputy Chief of Staff. Before that, he was Deputy Chief Administrative Officer for New Castle County, and on the staff of then-Senator Joe Biden. In these roles, he helped Delaware earn its first ever AAA bond rating, played a key role in the state’s purchase of the Port of Wilmington, and worked to cut taxes nine times. The second of nine children, John was born in Wilmington and raised in Claymont by his parents, Jack and Ann Carney, who were both educators. He attended St. Mark’s High School and led the school’s football team to its first state championship in 1973. After graduating high school, John attended Dartmouth College where he continued his football career and earned All-Ivy League and Most Valuable Player honors. When John returned to Delaware, he coached Freshmen Football on the staff of UD Head Coach Tubby Raymond while earning a Master’s Degree in Public Administration at the University of Delaware. John lives in Wilmington with his wife, Tracey. They have two sons, Sam and Jimmy.
Steven J. Stanhope Ph.D.
Steven J. Stanhope Ph.D.
Associate Vice President for Research and Principal Investigator | Delaware INBRE
Dr. Stanhope is a Professor in the Department of Kinesiology and Applied Physiology at the University of Delaware. He holds joint academic appointments in the Department of Mechanical Engineering and the Biomechanics and Movement Science Interdisciplinary Graduate Program. Dr. Stanhope received his Ph.D. degree in 1985 from the University of Maryland with concentrations in Biomechanics, Human Anatomy and Exercise Physiology. Between 1985 and 2001, he developed and directed the Biomechanics Laboratory in the Warren Grant Magnuson Clinical Center at the National Institutes of Health (NIH) in Bethesda, Maryland, USA. He is a founding member of both the SIAMOC and the Gait and Clinical Movement Analysis (GCMA) Societies. Dr. Stanhope served as GCMAS society President, and also as a member of the Society’s Board of Directors for two terms. Under the Reagan Administration, Dr. Stanhope led a series of technology development initiatives and in 1990, established the first of a series of Cooperative Research and Development Agreements (CRADAs) focusing on biomechanical instrumentation developments. In 1993, Dr. Stanhope received a patent for a “System and Method for Performing Simultaneous Bilateral Measurements on a Subject in Motion.” A pioneer in the development and dissemination of six-degree-of-freedom motion capture and analysis techniques, Dr. Stanhope led the development of NIH biomechanical analysis computer programs that by 1995 were used worldwide at over 48 clinical research facilities. In 1998, Dr. Stanhope crafted a multi-year technology transfer strategy which leveraged small business innovative research (SBIR) and technology transfer (STTR) grants, contributing to the establishment of C-Motion, Inc. – Currently, the world’s leading distributor of biomechanics software. At NIH, Dr. Stanhope was instrumental in designing key rehabilitation research facilities in the 870,000 square foot Mark O. Hatfield Clinical Research Center. In 2001, he occupied those facilities, becoming the founding Director of the Physical Disabilities Branch, a component of the National Institute of Child Health and Human Development and designated the NIH’s intramural rehabilitation research program. The goal of Dr. Stanhope’s research is to help people reach their optimal level of function when an injury, disease or other health related condition results in physical disability. His interests center on rehabilitation biomechanics and the clinical application of human motion capture, analysis and simulation methodologies. Specific topic areas include gait, balance, prosthetics and orthotics, modeling pediatric obesity, and more recently, joint stiffness, bone shape, rapid virtual prototyping of advanced prostheses and orthoses. Over the years, Dr. Stanhope has investigated a broad range of patient conditions including: limb sparing procedures in osteogenic sarcomas, femoral neuropathies, Proteus syndrome, chronic stroke, Parkinson’s disease, osteogenesis imperfecta, amputation, post polio syndrome, cerebral palsy, cerebellar ataxia and aging. Areas of research interest in his work include the development and implementation of novel devices and biomechanical measurement, modeling, and analysis techniques. This work has lead to the development of: a minimally invasive skeletal tracking method, a method for calibrating instrumented treadmills in situ, a novel body weight support system, and several commercially available products. Dr. Stanhope has co-authored more than 60 published works and holds United States letters of patent. His scientific review appointments for the NIH have included the initial review group for the Medical Rehabilitation Research Subcommittee and the Multidisciplinary Special Emphasis Panel, Special Study Section-5-2. He has served as a reviewer of Rehabilitation Engineering Research Center (RERC) grants for the National Institute on Disability and Rehabilitation Research (NIDRR) and for the National Science Foundation (NSF). Dr. Stanhope serves as a manuscript reviewer for several related biomechanics and rehabilitation publications. Prior to joining the University, Dr. Stanhope maintained adjunct faculty appointments in Biomedical Engineering at the Catholic University of America and in the Graduate Faculty of the University of Maryland Medical School. While at NIH, Dr. Stanhope also served as a senior mentor for graduate students at seven universities and in six disciplines (biomechanics and movement sciences, rehabilitation sciences, biomedical engineering, mechanical engineering, computer science, physics, and medicine). Since joining the University of Delaware in 2007, Dr. Stanhope has established: a Luminary Site Agreement with C-Motion, Inc. that supports the research efforts of more than 50 Faculty and students in theBiomechanics and Movement Science Program; a Cooperative Research and Development Agreement with the Advanced Design and Manufacturing division of the Department of Defense at Aberdeen, Maryland to build advanced orthoses; and a Cooperative Agreement with the Tuscan region of the Italian Health Care Ministry to study community-based Adaptive Physical Activity programs. He has served as the interim Dean of the College of Health Sciences, the university’s Research Integrity Officer, and is currently a member of numerous committees and councils (e.g., the Delaware Health Sciences Alliance Research & Development Task Force, the Partnership Initiative Coordinating Council, and Aging Cross College Cluster).
Dr. Jennifer Cheek
Dr. Jennifer Cheek
Director, Assay Development | Siemens Healthineers
Education: • PhD, University of South Carolina • NIH Postdoctoral Fellow, Michigan State University Current Role: • Project Lead LOCI COVID 19 Assays (Dimension EXL and Dimension VISTA) • Project Lead for ADVIA and Atellica Chemistry New Assays • REACH for ADVIA Chemistry /Atellica CH
Megan Carpenter
Megan Carpenter
Global Product Manager | Siemens Healthineers
Megan is a Global Product Manager at Siemens Healthineers where she is responsible for the product life cycle management of the clinical chemistry business for Atellica Solution. She graduated from the University of Delaware with a PhD in Molecular Biology and an MBA. Prior to Siemens, Megan served in R&D at CD Diagnostics (acquired by Zimmer Biomet) to develop first-to-market orthopedic diagnostic tests before transitioning into product management.
Doug Durney
Doug Durney
Product Manager | ILC Dover
Mr. Durney is the product line manager for ILC Dover’s personal protective equipment group. Early in his career, he started as a project engineer and then program manager for many of the company’s product development and production programs for the US Government working on advanced chem/bio respirators for both aircrew and ground troops. Mr. Durney subsequently worked as a key member of a diversification group helping transition the company into more commercial product ventures. As part of the commercial business, he has held roles in new product development, sales, and marketing of protective equipment and other customer-driven engineered solutions. Most recently he’s been heavily involved in the company’s efforts to support front line healthcare workers with advanced respiratory protection including the rapid development, production, and sales of a new innovative PAPR hood – the EZ BioHood™. He holds a bachelor’s degree in chemical engineering from the University of Delaware and an MBA from Wilmington University.
Vance Kershner
Vance Kershner
President & CEO | LabWare
LabWare develops and implements software for automating laboratory operations. This market is mostly known as LIMS (Laboratory Information Management Systems) and ELN (Electronic Laboratory Notebooks). LabWare is a global company with offices in 15 countries, employees in over 40 countries, and customers in about 90 countries. LabWare is a very flat organization, which is organized much along the lines of W.L. Gore, who also happens to be a LabWare customer. LabWare is privately held, with its’ Worldwide HQ in Wilmington Delaware. LabWare operates in a niche market with about 50 competitors, and enjoys about a 20% market share. LabWare sells to all types of industries, including Health Care. The Bio-Technology industry represents LabWare’s largest industry segment, in both number of customers, and in terms of revenue. Health care represents the largest opportunity for growth and has been a focus for several years. Vance expresses his engineering and artistic sides via special construction projects. Vance lives in a 100 year old home on Kentmere Parkway in Wilmington, which has been painstakingly renovated over the past five years. Kentmere is also the home of Vance’s extensive art collection. Some of Vance’s other interesting projects include restoring the Oberod Estate; operating a 15,000 acre game farm in South Africa (complete with a botanical garden in the bush); and is a partner in Scrub Island – the largest resort project ever undertaken in the BVI. Historically renovating Buckley’s Tavern in Centreville, DE is Vance’s latest project, which has been the talk of the town lately, since reopening in September. Vance enjoys running as a way to relax and stay in shape. Since giving up TV a few years ago, Vance now has time to read books. He enjoys wine, and imports many bottles each year from South Africa.